A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Key Inclusion Criteria:

• Must have a baseline (pre-dose on Day 1) Expanded Disability Status Scale (EDSS)between 0.0 and 5.0, inclusive.

• Must have experienced at least 1 documented relapse within the 12 months beforescreening, with a prior brain magnetic resonance imaging (MRI) demonstratinglesion(s) consistent with MS or have showed evidence of GdE lesion(s) of the brainon an MRI performed within the 6 weeks prior to screening.

Key Exclusion Criteria:

• An MS relapse that occurred within the 30 days prior to screening and/or theparticipant has not stabilized from a previous relapse prior to screening.

• Current hepatitis C infection and current hepatitis B infection. Participants withimmunity to hepatitis B from previous natural infection or vaccination are eligibleto participate in the study.

• History of severe allergic or anaphylactic reactions or of any allergic reactionsthat, in the opinion of the Investigator, are likely to be exacerbated by anycomponent of the study treatment.

• History or positive test result at screening for human immunodeficiency virus (HIV).

• Use at the time of enrollment and/or anticipated ongoing use of any traditionaland/or unlicensed medicines and/or traditional therapies and/or herbal preparations,which are known or considered by the Investigator to affect MS and endpoints thatare being considered in the study, including safety and efficacy.

• Current enrollment in any other investigational drug study or participation in anyother investigational study within 6 months prior to screening.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.